Hes repressors are essential regulators of hematopoietic stem cell development downstream of notch signaling by Guiu, J. (Jordi) et al.
Article
The Rockefeller University Press $30.00
J. Exp. Med. 2013 Vol. 210 No. 1 71-84
www.jem.org/cgi/doi/10.1084/jem.20120993
71
Hematopoietic stem cells (HSCs) originate dur-
ing embryonic life in association with arterial 
vessels including the aorta in the aorta/gonad/
mesonephros (AGM) region and the umbilical 
and vitelline arteries (Dzierzak and Speck, 2008). 
The first HSCs are detected around embryonic 
day (E) 10 of mouse development in hemato-
poietic clusters emerging from the ventral wall 
of the aorta in the AGM and are defined by their 
unique capacity to reconstitute hematopoiesis of 
immunodepleted adult recipients in transplanta-
tion assays. The Notch pathway is required for 
HSC development in the vertebrate embryo, 
upstream of Runx1 (Burns et al., 2005) and 
GATA-2 (Robert-Moreno et al., 2005), but is 
dispensable for yolk sac (YS) primitive hemato-
poiesis (Robert-Moreno et al., 2007; Bertrand 
et al., 2010; Bigas et al., 2010). Importantly, Gata2 
but not Runx1 expression was totally impaired 
in the aorta of Jag1/ mutant mouse embryos, 
which fail to generate hematopoiesis (Robert-
Moreno et al., 2005, 2008). Re-expression of 
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Previous studies have identified Notch as a key regulator of hematopoietic stem cell (HSC) 
development, but the underlying downstream mechanisms remain unknown. The Notch 
target Hes1 is widely expressed in the aortic endothelium and hematopoietic clusters, 
though Hes1-deficient mice show no overt hematopoietic abnormalities. We now demon-
strate that Hes is required for the development of HSC in the mouse embryo, a function 
previously undetected as the result of functional compensation by de novo expression of 
Hes5 in the aorta/gonad/mesonephros (AGM) region of Hes1 mutants. Analysis of embryos 
deficient for Hes1 and Hes5 reveals an intact arterial program with overproduction of 
nonfunctional hematopoietic precursors and total absence of HSC activity. These altera-
tions were associated with increased expression of the hematopoietic regulators Runx1,  
c-myb, and the previously identified Notch target Gata2. By analyzing the Gata2 locus, we 
have identified functional RBPJ-binding sites, which mutation results in loss of Gata2 
reporter expression in transgenic embryos, and functional Hes-binding sites, which muta-
tion leads to specific Gata2 up-regulation in the hematopoietic precursors. Together, our 
findings show that Notch activation in the AGM triggers Gata2 and Hes1 transcription, and 
next HES-1 protein represses Gata2, creating an incoherent feed-forward loop required to 
restrict Gata2 expression in the emerging HSCs.
© 2013 Guiu et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Figure 1. Increased hematopoietic cluster emergence in Hes-deficient embryonic aortas. (A) Transversal sections of embryos at 10.5 d showing 
expression of Hes5 and Hes1 by in situ hybridization (ISH). Arrowheads indicate the structures (Ao, aorta; IAHC, intra-aortic hematopoietic cluster;  
m, mesonephros; nt, neural tube; p2, p2 neural progenitors; SG, sympathetic ganglia). Details of IAHC and aorta in the right panels correspond to the boxed 
areas in the middle panels. (B) Relative expression of the indicated genes from E10.5 dissected AGMs after 3 d of 4-OH-tamoxifen treatments in explant 
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GATA-2 partially rescued generation of hematopoietic cells 
from Jag1/ AGM cells (Robert-Moreno et al., 2008), con-
sistent with its pivotal role in definitive embryonic and adult 
hematopoiesis (Tsai et al., 1994).
The Notch signaling pathway and its function in control-
ling cell fate diversification is conserved through evolution. 
Notch receptors interact with their ligands that are expressed 
on neighboring cells, and this interaction induces two se-
quential proteolytic events, which release the intracellular 
Notch (ICN) fragment. Once activated, Notch associates 
with its specific coactivator Mastermind (Mam) and the nu-
clear factor RBPJ to induce a transcriptional response, gener-
ally associated with the inhibition of a particular cell fate 
destiny from a population of equivalent cells (Kopan and 
Ilagan, 2009). Classical examples of Notch-dependent fate in-
hibition are B cell differentiation in the hematopoietic sys-
tem, secretory lineage in the adult intestine, and the neural 
fate from neural/glial precursors. Most of these Notch re-
sponses are context dependent and associated with regulation 
of tissue-specific targets; however, a group of Notch target 
genes belonging to the Hairy/Enhancer of split (HES) family are 
known to mediate Notch actions in a wide range of cell types 
and organisms (Kageyama et al., 2007). We previously found 
that activation of Notch in the AGM was concomitant with 
the transcriptional expression of Hes1 and Hes-related family 
genes (Robert-Moreno et al., 2005).
HES proteins are bHLH transcriptional repressors includ-
ing the Notch targets HES-1, HES-3, HES-5, HES-7, and 
the HES-related proteins HRT-1 and HRT-2 (Kageyama 
et al., 2007). In the hematopoietic system, HES-1 has a major 
function in normal T cell development, but it is also directly 
involved in the maintenance of Notch-induced T cell leuke-
mias (Tomita et al., 1999; Espinosa et al., 2010; Wendorff  
et al., 2010). In addition, ectopic HES-1 inhibits differentiation 
of bone marrow HSCs when cultured in vitro (Kunisato et al., 
2003); however, nothing is known about a putative role of 
HES in regulating embryonic hematopoiesis or HSC genera-
tion. In this study, we investigate the mechanisms that con-
trol HSC development downstream of Notch and demonstrate 
that HES repressors are essential for regulating the levels of 
Gata2 in the AGM precursors and generate functional hema-
topoietic cells.
RESULTS
Increased hematopoietic cluster emergence  
in Hes-deficient embryonic aortas
Hes1 is expressed in the aortic endothelium and the presump-
tive hematopoietic clusters of the AGM region (Fig. 1 A; 
Robert-Moreno et al., 2008), suggestive of a hematopoietic 
function. However, Hes1-null embryos contain functional 
HSCs and progenitors in the fetal liver that are able to recon-
stitute all hematopoietic lineages except T cells when trans-
planted into RAG2-null mice. We explored the possibility 
that other Hes members compensate for Hes1 deficiency dur-
ing hematopoietic development, similarly to what occurs in 
the nervous system (Ohtsuka et al., 1999). To this purpose, 
we used two genetic models, the first one carrying a constitu-
tive deletion of Hes1 and Hes5 alleles in different combina-
tions and the second with constitutive deletion of one or two 
copies of Hes5 combined with Hes1-loxP alleles, which can 
be deleted after tamoxifen treatment when crossed with mice 
carrying the -actin–CRE-ERT transgene. We first deter-
mined whether deletion of several Hes1 and Hes5 alleles 
in the AGM affects the expression of other members of this 
family of repressors. Importantly we found that Hes5, which 
is not detected in the endothelium nor hematopoietic clusters 
of wild-type AGM (Fig. 1 A), was highly induced in both 
tissues after genetic deletion of Hes1 (Fig. 1, B and C). In 
contrast, other Hes family genes such as Hrt1/Hey1 and Hrt2/
Hey2 were not affected (Fig. 1 B). Notch activity but also 
HRT-1 and HRT-2 functions are essential to induce the 
arterial program (Fischer et al., 2004), which constitutes the 
niche for HSC generation. Thus, we tested whether combined 
Hes1/5 deficiency precludes arterial development in the AGM. 
Analysis of E10.5 embryo sections stained with the pan-
endothelial/hematopoietic CD31 marker did not reveal any 
apparent vascular abnormality in the AGM aorta at this stage 
(Fig. 1 F and not depicted). Moreover, by immunostaining 
cultures by qRT-PCR. Fold increase to the wild-type control after 2-Microglobulin and GAPDH normalization. Bars represent the mean ± SD determina-
tion from two experiments showing the fold increase versus the wild-type AGM. (C) Relative expression of Hes5 from sorted populations (endothelial, 
CD31C-KitCD45; hematopoietic clusters, CD31+C-Kit+) by qRT-PCR. mRNA was extracted from a pool of 10 AGMs at E10.5 in Hes1+/+ Hes5+/+ determi-
nations and 4 AGMs in Hes1f/f Hes5+/ -ACTIN–CRE-ERT after in vivo tamoxifen induction at E8. Bars represent the mean ± SD determination from one 
representative of two experiments showing the fold increase versus the wild-type AGM after 2-Microglobulin normalization. (D) Representative immuno-
staining of CD44 and SMA (arterial markers) in the AGM region in wild-type or Hes mutant embryos on E10.5 (A, dorsal aorta; Ao, aorta in AGM region; 
cv, cardinal vein; m, mesonephros; nt, neural tube). (E) Relative expression of endothelial (PECAM1), arterial markers (EphrinB2, smooth muscle actin 
[SMA], and CD44), and vein marker (EphB4) in E10.5 AGM after 3 d of 4-OH-tamoxifen treatment in explant culture from embryos with the indicated 
genotypes (n = 3 each genotype) by qRT-PCR. Bars represent the mean ± SD determination from three experiments showing the fold increase relative to 
the wild-type AGM. (F) Representative immunostaining of CD31 (endothelial and hematopoietic) and CD41 (hematopoietic precursors) in the AGM region 
in wild-type or Hes mutant embryos. Arrowheads indicate the structures. Bars: (A and D) 200 µm; (F) 50 µm. (G) Quantification of CD41+ cells per mi-
crometer of AGM. Spearman test was used to assess the significance between wild-type allele number and CD41+ cells per micrometer. Correlation be-
tween number of wild-type alleles and CD41+ cells per micrometer was significant (**, P < 0.001; and  = 0.985). Bars represent the mean of counted cells 
in two different embryos ± SEM. (H) CD41+ clusters containing more than four cells per micrometer of AGM. Quantification of CD41+ cells per micrometer 
of AGM. Spearman correlation was used to assess the significance between number of wild-type alleles and CD41+ clusters containing more than four 
cells per micrometer (**, P = 0.005; and  = 0.803). Bars represent the mean of counted clusters in two different embryos ± SEM.
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Figure 2. Occupancy of the Gata2 promoter by HES-1 and Notch/RBPJ. (A) Relative expression of the indicated genes from E10.5 AGM after 3 d 
of 4-OH-tamoxifen treatments in explant cultures by qRT-PCR. Fold increase relative to the wild-type control after 2-Microglobulin and GAPDH normal-
ization. Spearman test was used to assess the significance between number of wild-type alleles and gene expression indicated on the top of the figure. 
Correlation between number of wild-type Hes alleles and Gata2 expression was significant (P ≤ 0.001 and  = 0.985) but not for c-Myb (P = 0.126 and  
 = 0.985) and Runx1 expression (P = 0.072 and  = 0.591). The mRNA levels of Runx1, Gata2, and c-Myb are significantly up-regulated in cells with three  
to four deleted compared with zero to one deleted hes alleles (Student’s t test, P < 0.05). Bars represent the mean ± SD fold increase determination from 
two independent experiments. (B) Representative in situ hybridization of Gata2 in the wild-type (n = 2) or Hes mutant embryos (n = 2, each genotype). 
Images show transversal section of E10.5 embryos in the AGM region. Arrowheads indicate the structures (Ao, aorta; IAHC, intra-aortic hematopoietic 
JEM Vol. 210, No. 1 
Article
75
and quantitative RT-PCR (qRT-PCR), we found that dif-
ferent arterial-associated genes including EphrinB2 and SMA 
remained unaffected in these mutant embryos (Fig. 1, D and E). 
These results indicate that HES repressors are dispensable 
for maintaining the arterial program in the embryo. A more 
accurate analysis of the AGM aorta stained for CD31 (label-
ing endothelial and hematopoietic cells) demonstrated that 
Hes1/Hes5+/ and Hes1/Hes5/ mutant embryos have 
larger hematopoietic cluster structures when compared with 
wild-type embryos (Fig. 1 F). We confirmed the hematopoi-
etic nature of these clusters by staining with anti–C-Kit (not 
depicted) and CD41 (Fig. 1 F). Quantification of CD41+ cells 
in the AGM from different wild-type and mutant embryos 
demonstrated that the number of Hes1 and Hes5 deleted 
alleles inversely correlated with the total number of hemato-
poietic progenitors per AGM present in the aortic endothelium 
(up to 10-fold; Spearman’s correlation, P < 0.001; Fig. 1 G) 
and the number of enlarged clusters with more than four cells 
(Spearman’s correlation, P = 0.004; Fig. 1 H), indicating func-
tional compensation between Hes1 and Hes5 in the AGM.
Occupancy of the Gata2 promoter  
by HES-1 and Notch/RBPJ
Next, we determined the expression levels of different hema-
topoietic transcription factors in the AGM clusters from wild-
type and mutant embryos. We found that Runx1, c-myb, and 
Gata2 were significantly overexpressed in Hes-deficient em-
bryos compared with the wild type (or deletion of one Hes 
allele; Fig. 2 A). Importantly, expression levels of Gata2 but 
not of Runx1 and c-myb in the embryonic AGM directly and 
significantly correlated with the number of deleted Hes1/5 al-
leles in the mutants (Spearman’s correlation, P < 0.001; Fig. 2 A). 
Increase in Gata2 levels was also detected by in situ hybrid-
ization of the whole AGM region of Hes1/Hes5+/ em-
bryos. Specifically, Gata2 mRNA was up-regulated in the 
hematopoietic clusters, mesenchyme, mesonephros, urogeni-
tal ridge, and mesentery lining of these mutant embryos when 
compared with the wild type (Fig. 2 B).
Previous data from our group indicated that Gata2 is a 
downstream target of Notch in the AGM (Robert-Moreno 
et al., 2005). By sequence analysis of the Gata2 locus using 
Genomatix software, we have now identified the presence of 
two RBPJ and three HES motifs that are conserved in both 
the human and mouse Gata2 gene (Fig. 2, C and D). Because 
HES-1 is the main Notch target and a well-characterized 
transcriptional repressor, we hypothesized that Notch might 
activate Gata2 transcription that is next antagonized by 
Notch-mediated induction of HES-1. To address this possi-
bility, we first conducted chromatin immunoprecipitation 
(ChIP) analysis using 32D myeloid progenitor cells to deter-
mine the recruitment of RBPJ, ICN1, and HES-1 proteins to 
the Gata2 locus. We tested Gata2 occupancy using primers 
that amplify 15 regions spanning from 3033 to 5827 rela-
tive to the TSS at the IS promoter (Fig. 2 E). Of note, Gata2 
can be transcribed from two different promoters (IS and IG), 
both yielding the same protein but using a different first 
untranslated exon (Minegishi et al., 1999), with IS being 
hematopoietic/neural specific (Nagai et al., 1994) and IG  
the general Gata2 promoter. Our analysis revealed RBPJ and 
ICN1 occupancy in the 800 to 14 region, which contains 
two of the three predicted RBPJ-binding sites, whereas 
HES-1 protein was found associated at the 3059 to 5203 region, 
which contains the three predicted HES-1 sites (Fig. 2 E). 
A similar pattern for Notch1, RBPJ, and HES-1 association 
was detected using dissected AGM tissue (Fig. 2, F and G) and 
human K562 myeloerythroid cells (not depicted). Interest-
ingly, we failed to detect RBPJ or HES binding to the Gata2 
promoter in mouse NIH-3T3 fibroblasts (not depicted). 
These results indicated that RBPJ/Notch proteins occupy the 
IS promoter, whereas HES-1 binds the IG promoter of the 
Gata2 gene specifically in hematopoietic cells.
HES-1 is a negative regulator of the Gata2 promoter  
in hematopoietic cells
Previously, we demonstrated that embryos with deficient 
Notch activity failed to express Gata2, and we presented evi-
dence that Gata2 is a transcriptional Notch target (Robert-
Moreno et al., 2005). However, ectopic expression of ICN1 
in AGM cells does not increase Gata2 transcription (not de-
picted), which could be explained by a negative regulation of 
the Gata2 promoter by HES-1. To test this possibility, we ana-
lyzed different Gata2 regulatory regions (Fig. 3 A) for their 
capacity to respond to ectopically expressed ICN1 or HES-1. 
We found that Gata2p-IS, containing RBPJ sites, but not 
Gata2p-IG, was transcriptionally induced by the Notch co-
activator Mam1 in a dose-dependent manner and repressed by 
a dominant-negative RBPJ (Fig. 3 B). Furthermore, Gata2p-IS 
promoter was activated two- to fourfold by ICN1 after inhi-
bition of endogenous Notch activity by DAPT (Fig. 3 B and 
not depicted). By mutational analysis, we found that both pre-
dicted RBPJ-binding sites in the Gata2p-IS promoter were 
functional because only elimination of the two sites impaired 
the capacity of this reporter to be activated by Notch (Fig. 3 C). 
In similar experiments, Gata2p-IG reporter was repressed by 
cluster; m, mesonephros; nt, neural tube). Details of IAHC in the right panels correspond to the boxed areas in the left panels. Bars: (left) 200 µm; (right) 
20 µm. (C) Graphical representation of the mouse Gata2 promoter showing the putative RBPJ- or HES-binding consensus found by bioinformatic analysis. 
Asterisks indicate the conserved sites in the human Gata2 locus (IS, specific promoter; IG, general promoter). (D) Sequence and location of the human 
and mouse conserved RBPJ- and HES-binding sites relative to IS and IG promoters. (E) ChIP with the anti–HES-1, anti-ICN1, anti-RBPJ, and anti-IgG anti-
bodies from myeloid 32D cells and analysis of the Gata2 locus by qPCR. One representative of two experiments is shown. (F and G) ChIP with the anti–
HES-1, anti-ICN1, anti-RBPJ, and anti-IgG antibodies from E10.5 AGM cells and analysis of the Gata2 locus by qPCR. One representative from three 
experiments is shown. (E–G) Error bars represent SD from qPCR values.
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detected a similar significant increase of both IS and IG mRNA 
in the AGM from Hes-deficient embryos, suggesting that 
Notch and HES are globally affecting the Gata2 locus. Together, 
these results indicate that Notch and HES coregulate expres-
sion of the Gata2 promoter in vitro in an opposite manner.
Notch/RBPJ and HES control Gata2 expression  
during embryonic development
To test whether Notch and HES control Gata2 expression in 
the embryo, we generated point mutations for both RBPJ 
sites (p7.0IS RBP12) on the previously characterized Gata2-IS 
reporter construct (p7.0IS WT; Fig. 4 A; Minegishi et al., 
ectopic HES-1 expression and activated in cells transduced 
with Hes1-specific shRNA (Fig. 3, D and E). Mutational 
analysis demonstrated that all three HES-binding sites were 
functional and sufficient to repress Gata2 reporter expression 
because only the combined mutation of all three sites relieved 
Gata2 repression by HES-1 (Fig. 3 E). As we previously 
showed that Jagged1 is the Notch ligand required in the AGM 
for the hematopoietic development (Robert-Moreno et al., 
2008), we next measured the levels of IS and IG Gata2 mRNA 
in AGM from embryos deficient for Jagged1 by qRT-PCR 
and found that both transcripts are equally down-regulated 
in the absence of Notch activation (Fig. 3 E). Moreover, we 
Figure 3. HES-1 is a negative regulator of the Gata2 promoter in hematopoietic cells. (A) Scheme of the Gata2 locus indicating the conserved 
RBPJ- and HES-binding sites (vertical arrows). Promoter regions were used in the luciferase assay. (B) Luciferase activity from the Gata2p-IS and Gata2p-IG 
promoter in the presence or absence of ICN1, Mam1, or dn-RBP in HEK-293T cells (**, P ≤ 0.009). The dotted line in the Western blot (WB) indicates that 
intervening lanes have been spliced out. (C) Luciferase activity from the Gata2-IS promoter with indicated point mutations in the RBPJ-binding consen-
sus (bold/underlined) measured in HEK-293T cells. DAPT incubation was used to reduce endogenous Notch activity. (D) Luciferase activity of the Gata2-IG 
promoter in the presence or absence of HES-1. (E) Luciferase activity from the Gata2-IG promoter with the indicated point mutations (bold/underlined) in 
the HES-binding consensus. (B–E) Mean ± SD of at least three independent experiments is shown in all the plots; Student’s t test was used to assess the 
significance (*, P < 0.05). (F) Relative expression of the indicated genes from independent determinations of fresh E10.5 AGMs in Jagged1+/+ (n = 3) and 
Jagged1/ (n = 3) and E10.5 AGMs in Hes1-5 wild type (n = 2) and knockouts (n = 3) by qRT-PCR after 3 d of 4-OH-tamoxifen treatments in explant 
cultures. Fold increase to the wild-type control after GAPDH normalization is shown. Bars represent the mean ± SD determination; Student’s t test was 
used to assess the significance (*, P < 0.05).
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examined at E10.5 (Fig. 4 B). In embryos carrying the wild-
type reporter, we found specific expression of GFP in the 
dorsal aorta and neural tissue (3/4 transgene-positive embryos 
1999, 2003) and microinjected mutant or wild-type DNA 
into fertilized oocytes. The expression patterns of GFP driven 
by these promoters in the transgenic F0 (founders) mice were 
Figure 4. Notch/RBPJ and HES-1 regulate 
Gata2 promoter in vivo during embryonic 
development. (A) Schematic representation of 
the Gata2 promoter constructs analyzed in vivo. 
(B) Representative brightfield (left) and fluorescent 
(right) micrographs of embryos containing the 
wild-type or RBPJ mutant Gata2p7.0IS construct 
at E10.5. Arrowheads indicate the structures (FL, 
fetal liver; me, mesencephalon). Summary of the 
data from at least three independent experiments 
is indicated at the bottom. Fisher test was used to 
assess the significance. (C) Transversal section of 
the AGM region and neural tube (nt) of E10.5 em-
bryos containing the indicated constructs showing 
expression of GFP as detected by immunostaining. 
Nuclear staining by DAPI is represented in blue. 
Arrowheads indicate the structures (Ao, aorta; 
IAHC, intra-aortic hematopoietic cluster; m, meso-
nephros; p2, neural tube p2 domain). Bars: (B) 2 mm; 
(C) 200 µm. (D) Flow cytometry analysis of GFP in 
the indicated CD31+ subpopulation of E10.5 AGM 
cells from two representative embryos contain-
ing the p4.0 wild-type or mutant for HES sites.  
(E and F) Mean percentage (E) and mean intensity (F) 
of GFP+ cells in the endothelial (CD31+C-KitCD45),  
prehematopoietic (CD31+C-Kit+CD45), and HSC/P 
(CD31+C-Kit+CD45+) populations from three  
transgene-positive embryos from at least two inde-
pendent experiments (**, P = 0.01). Error bars  
represent SEM.
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Figure 5. AGM hematopoietic clusters in Hes-deficient embryos lack functional progenitors and HSCs. (A) Determination of CFU-C hematopoietic 
progenitors obtained from E10.5 AGM after 3 d of explant culture in the presence of 4-OH-tamoxifen to induce Hes1 deletion. Kruskal–Wallis and Mann–
Whitney U tests were used to assess the significance. Mean ± SEM from three or more AGM explants from at least three independent experiments is shown. 
PCRs from isolated colonies to test Hes1 deletion are shown. (B) Flow cytometry analysis from CD34+C-KIT+ sorted cells from E9.5 and E10.5 embryos with the 
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as determined by PCR) as previously reported (Minegishi 
et al., 2003). Importantly, mutations in the core of the RBPJ-
binding sites abolished the expression of the reporter gene in 
both the aorta and the neural tissue (0/9 transgene-positive 
embryos by PCR). Immunostaining with anti-GFP in em-
bryo sections confirmed the expression pattern for the Gata2 
reporter in wild-type embryos and the absence of GFP in the 
aorta or neural tube of embryos carrying the RBPJ mutant 
reporter (Fig. 4 C). These results indicate that Notch/RBPJ 
activity is required for driving Gata2 transgene expression 
from the IS promoter in both hematopoietic and neural tis-
sues. We performed comparable experiments using the p4.0 
reporter with mutations of all three HES sites. This reporter 
contains the 4 to 5 kb sequence of the mouse Gata2 locus 
(including IS and IG promoter regions) and recapitulates the 
expression pattern of the endogenous Gata2 gene in trans-
genic embryos (including expression in the AGM and neural 
tube; Minegishi et al., 1999, 2003). Based on our in vitro data, 
we predicted that HES-binding site mutations might either 
increase the reporter levels within a particular cell popula-
tion or change the cell type specificity of the reporter. There-
fore, as readout for these experiments, we determined GFP 
levels in specific hematopoietic (CD31+/C-Kit+CD45+), 
prehematopoietic (CD31+C-Kit+CD45), and endothelial 
(CD31+C-KitCD45) cell populations from E9.5–10.5 trans-
genic embryos (26–35 somite pairs). Our results demonstrate 
that the wild-type reporter was expressed at low levels in all the 
AGM subpopulations. Interestingly, HES mutant reporter led 
to an increased percentage of GFP-positive cells that was not 
significant in the endothelial lineage (from 8 ± 2.6% to 18.1 ± 
4.6%; P = 0.07) or in the committed HSC and progenitors 
(HSC/Ps; from 6 ± 3% to 24 ± 16%; P = 0.13) but reached 
statistical significance in the prehematopoietic population 
(from 6.2 ± 4.6% to 38 ± 10%; P = 0.015; Fig. 4, D and E). 
Moreover, hematopoietic cells carrying the mutant reporter 
showed increased expression levels of GFP (Fig. 4, D and F). 
These results demonstrate that Notch is required for Gata2 ex-
pression in the AGM, whereas HES restricts the levels of Gata2 
specifically within the presumptive AGM hematopoietic cells.
AGM hematopoietic clusters in Hes-deficient embryos  
lack functional progenitors and HSCs
We have shown that Hes deficiency results in enlarged he-
matopoietic clusters in the developing AGM. To test the 
functionality of these mutant hematopoietic cells, we used the 
mouse line containing the tamoxifen-inducible -actin–CRE-
ERT transgene in different combinations of the loxP-Hes1 
and the Hes5 deleted alleles. E10.5 AGMs of the different 
genotypes were dissected and cultured as explants for 3 d 
in the presence of 4-OH-tamoxifen to induce the deletion. 
Dissociated AGM cells were then plated in methylcellulose 
to determine the number of hematopoietic progenitors by 
colony-forming cell (CFC) assays. We found that AGM cells 
containing three deleted Hes alleles showed significantly dif-
ferent number of functional progenitors (CFC) when com-
pared with those carrying one or two deleted alleles (Fig. 5 A). 
These results suggest that a minimum threshold of HES levels 
(two wild-type alleles) is required to maintain the function-
ality of hematopoietic progenitors. Interestingly, CFC assay 
of E10.5 YS cells revealed that progenitors contained in the 
extraembryonic tissue are not significantly affected in the 
-actin–CRE-ERT loxP-Hes1 R26-YFPf/+ Hes5+/ embryos 
(not depicted), in agreement with previous findings showing 
the Notch-independent formation of YS progenitors (Robert-
Moreno et al., 2007; Bertrand et al., 2010). Analysis of the 
colonies by PCR confirmed the deletion of the inducible 
alleles after tamoxifen treatment (Fig. 5 A). Furthermore, 
hematopoietic progenitors (defined as CD34+C-Kit+) isolated 
from constitutive Hes1/Hes5/ embryos were unable to 
produce sca1+C-Kit+ progenitors and CD45+ hematopoietic 
cells when cultured on OP9 stroma, compared with Hes5/ 
cells (Fig. 5 B).
To measure the number and functionality of Hes-deficient 
hematopoietic progenitors in an in vivo system, we deter-
mined the capacity of dissociated AGM cells from tamoxi-
fen-treated explants of different genotypes to generate 
spleen colonies (CFU-S11) in lethally irradiated mice. As 
Hes1f/fHes5/ mutant animals were obtained on a mixed 
background, we used immunodeficient SCID-Beige mice as 
recipients for the transplants to avoid graft rejection. In these 
experiments, we obtained a mean number of 16.6 ± 1.4 
CFU-S11 from one wild-type E10.5 AGM explant (1 embryo 
equivalent [1 ee]), similarly to that obtained from Hes5/ 
AGM explants (Fig. 5, C and D; and not depicted). In con-
trast, the number of colonies obtained from AGM explants 
with all four Hes alleles deleted was comparable with the 
noninjected/irradiated controls (4 ± 0.3; Fig. 5, C and D), and 
the few colonies detected did not contain Hes1 deletion 
indicated genotypes cultured on OP9 with factors (SCF+IL3+Epo+G-CSF) for 10 d. Dot plots are representative of three independent experiments. (C) Spleen 
colonies from 4-OH-tamoxifen–treated E10.5 AGM explants from the indicated genotypes injected in irradiated SCID-Beige mice. Mean of (CFU-S11) from 
three or more injected animals is shown. Student’s t test was used to assess significance. Error bars represent the mean of colonies in the spleens analyzed. 
(D) Representative spleen images (top) and PCR from dissected spleen colonies to test for Hes1 deletion (bottom) are shown. (E) Flow cytometry analysis at  
2 mo of SCID-Beige transplanted animals. Each mouse was transplanted with 2 ee AGMs after 3 d of 4-OH-tamoxifen treatments in explant culture. Two repre-
sentative controls (n = 4) and two Hes1f/fHes5+/ R26-YFPf/+ -actin–CRE-ERT (n = 3) are shown. Controls with >1% of YFP cells were considered as reconsti-
tuted. (F) Quantification of Ki67 and TUNEL within the CD31-positive cells from immunostainings (n = 2 each genotype) of Ki67/CD31 and TUNEL/CD31 in the 
AGM region in wild-type or Hes1f/fHes5/ -actin–CRE-ERT mutant embryos after in vivo tamoxifen induction at day E8. Error bars represent the mean of 
positive cells from the different embryos analyzed. (G) Gating strategy to analyze the different subpopulations by flow cytometry analysis of fresh E10.5 
AGMs with functional HSC phenotype (zero to one Hes deleted alleles; n = 4) or with nonfunctional HSC phenotype (three to four Hes deleted alleles; n = 3) 
after in vivo 4-OH-tamoxifen induction at E8. (H) Bars represent the mean percentage ± SD of positive cells of the indicated populations.
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hematopoietic cells in the AGM, we aimed to reduce Gata2 
levels in the Hes-deficient AGM cells. Because Gata2 ex-
pression is dependent on Notch activity, we anticipated that 
incubation of Hes-deficient cells with limited concentra-
tions of Notch/-secretase inhibitors should lead to a de-
crease of Gata2 levels that would be compatible with the 
hematopoietic development.
After testing different DAPT concentrations, we found that 
incubation of Hes-deficient AGM cells in liquid cultures con-
taining 0.05 µM DAPT resulted in a substantial decrease of 
Gata2 levels, resembling the levels detected in DMSO-treated 
wild-type AGM cells (Fig. 6 A). In these conditions, Hes-defi-
cient AGM cultures produced increased numbers of CD45+ 
cells compared with the DMSO-treated Hes-deficient cul-
tures (Fig. 6 B). Conversely, incubation of wild-type AGM cells 
with the same dose of DAPT (or higher) resulted in a de-
crease in CD45+ cell production as previously published 
(Robert-Moreno et al., 2008). These results indicate that the 
positive hematopoietic effect of DAPT observed in Hes-
deficient cells is not directly mediated by changes in Notch activ-
ity but by a downstream target of Notch and Hes. Based on this 
data, we propose the existence of a permissive threshold of 
Gata2 levels that is acquired by the combined action of Notch 
and Hes repressors that allow hematopoietic development in 
the AGM (see model in Fig. 6 C). Together, these results indi-
cate that HES proteins are responsible for the control of Gata2 
levels downstream of Notch signaling, which is essentail for the 
generation of HSCs during embryonic development.
DISCUSSION
Deciphering the molecular events that control hematopoietic 
development is a crucial issue for understanding how func-
tional HSCs are produced and maintained. In this work, we 
focused on the role of HES proteins, which are the principal 
mediators of the Notch pathway in multiple systems.
Fetal liver of Hes1-deficient embryos had been previously 
analyzed, and no major defects on HSC activity were found 
(Fig. 5 D, bottom). We next determined the existence of func-
tional HSCs after induction of Hes1 deletion in E10.5 AGM 
explants from the -actin–CRE-ERT loxP-Hes1 R26-YFPf/+ 
Hes5+/ background compared with the -actin–CRE-ERT 
R26-YFPf/+. To increase the repopulating capacity of E10.5 
AGM, we injected 2 ee per each SCID-Beige recipient to-
gether with spleen cells as a support. In these experiments, we 
did not detect any HSC activity from Hes-deficient AGM 
cells (three alleles deleted), whereas all mice transplanted with 
control cells showed hematopoietic multilineage reconstitu-
tion after 8 wk (n = 4, considering >1% of donor cells in pe-
ripheral blood; Fig. 5 E and not depicted).
Although these results indicate that E10.5 Hes-deficient 
embryos (deletion induced in vivo at E8.5) do not contain 
functional HSC/Ps, their AGMs contained higher numbers of 
CD41+ and C-Kit+ cluster cells (Fig. 1, F–H; and not depicted). 
To further understand how Hes deficiency contributes to this 
particular phenotype, we determined by immunofluorescence 
the number of TUNEL- and Ki67-positive cells in the CD31+ 
cells of sections from E10.5 wild-type and -actin–CRE-ERT 
loxP-Hes1Hes5/ embryos treated with tamoxifen at E8.5. 
We found that CD31+ cells of the AGM contain a significantly 
higher number of Ki67+ cells and very low but comparable 
numbers of TUNEL+ cells (Fig. 5 F). Most importantly, a 
detailed analysis of the different subpopulations contained 
within the CD31+ population of the AGM (hematopoietic 
clusters plus endothelium) demonstrated that whereas the 
C-Kit+CD41+CD45 (pre-HSC) population was increased 
upon Hes deletion, the C-Kit+CD41+CD45+ population that 
defines the committed HSCs was significantly decreased 
(Fig. 5, G and H). These results suggest that Hes deficiency in-
duces higher proliferation in the AGM clusters while prevent-
ing prehematopoietic cells to reach the HSC stage.
Reduction of Notch signaling partially rescues  
the Hes-dependent hematopoietic defect
To investigate the putative connection between overex-
pression of Gata2 and overproduction and nonfunctional 
Figure 6. Reduction of Notch signaling partially res-
cues Hes-dependent hematopoietic defect. (A) Wild-
type and Hes1f/fHes5/ -actin–CRE-ERT E10.5 dissected 
AGMs after in vivo tamoxifen induction at E8.5, disrupted 
with collagenase, and plated in liquid culture in the pres-
ence of cytokines (IL6, IL3, and SCF), DMSO, or 0.05 µM 
DAPT; mRNA was obtained to quantify the levels of Gata2 
after 24 h. Bars represent the mean ± SD determination  
(n = 3 each condition). (B) In parallel, cultures were analyzed 
after 6 d by flow cytometry to quantify the amount of cells 
CD45+ (wild type, n = 4; Hes1f/fHes5/ -actin–CRE-ERT, 
n = 10). (C) In the presence of HES-1, Gata2 levels are 
limited to the just-right dose to generate functional HSC/P. 
(D) In the absence of Hes1, Gata2 levels cannot be re-
pressed and result in the generation of a great number of 
nonfunctional progenitors.
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In this work, we have dissected the effects of a single Notch 
pathway mediator (HES) during the generation of HSCs. 
However, this is an extremely simplified picture of the Notch-
dependent regulatory networks occurring during this process, 
and many other elements and pathways will be sequentially 
incorporated into the final model. One example is the restric-
tion imposed by the availability of Notch ligands to the 
Notch-responding cell that will depend on other upstream 
signals such as WNT (Estrach et al., 2006; Rodilla et al., 2009), 
the specificity of Notch for its ligands that is modulated by 
Fringe-mediated glycosylation (Koch et al., 2001), or other 
interactions with the niche, which will be crucial to achieve 
the proper intensity of Notch signal in individual AGM cells. 
Another variable is HES-1 protein stability, which is regulated 
by the JAK–STAT pathway and directly impacts HES oscilla-
tion (Yoshiura et al., 2007). In addition, Hes1 transcription 
itself is controlled by a negative autoregulatory feedback loop 
(Hirata et al., 2002). Finally, a complex network of interac-
tions that involves FLI1 and SCL and operates downstream of 
Notch and GATA-2 in the HSC and hematopoietic precursors 
has already been modeled (Narula et al., 2010). In summary, 
we have here deciphered the first mechanism downstream of 
Notch signaling that regulates HSC development.
MATERIALS AND METHODS
Animals. CD1, C57B6/J wild-type, and Jagged1/ (Xue et al., 1999), 
Hes1/;Hes5/ (Ohtsuka et al., 1999), Hes1f/f (Imayoshi et al., 2008), and 
-actin–CRE-ERT (Hayashi and McMahon, 2002) strains were used. R26-
RYFPf/f (strain name: B6.129X1-GT(ROSA)26Sortm1(EYFP)Cos/J) was obtained 
from the Jackson Laboratory. C57BL6/J oocytes were used in F0 assays. 
SCID-Beige animals were used as recipients in CFU-S11 and long-term re-
constitution experiments. Animals were kept under pathogen-free condi-
tions, and all procedures were approved by the Animal Care Committee of 
the Parc de Recerca Biomèdica de Barcelona (regulation of Generalitat de 
Catalunya). Embryos were obtained from timed pregnant females and staged 
by somite counting: E10.5 (31–40 sp). The detection of the vaginal plug was 
designated as day 0.5. Mice and embryos were all genotyped by PCR.
qRT–PCR. Total RNA was extracted with a QIAGEN kit, and RT-First 
Strand cDNA Synthesis kit (GE Healthcare) was used to produce cDNA. 
qRT-PCR was performed in a LightCycler480 system using SYBR Green I 
Master kit (Roche). Primers used are in Table S1.
Promoter analysis, site-directed mutagenesis, and luciferase assays. 
Human and mouse Gata2 promoters were analyzed using Genomatix soft-
ware. For luciferase assays, Gata2p-IG was previously described (Minegishi 
et al., 1998), which covers from 482 of IG transcript to exon 2. Gata2p-IS 
was generated cloning the region from 794 to 93 of exon IS into the 
pGL3 vector and verified by sequencing. The primers used were Fwd 
(5-AAAACTCGAGGGTGCTACAAGGATGTGGTTGC-3) and Rev 
(5-AAAAAAGCTTGCTATGGTTGAGGTGATCTTAGGC-3). Muta-
tions were introduced into wild-type plasmids using the QuikChange Site-
Directed Mutagenesis kit from Agilent Technologies according to the 
manufacturer’s instructions. The mutations introduced and primers used are 
specified in Table S2. All mutations were verified by DNA sequencing.
Luciferase reporter assays were performed in HEK-293T cells. Cells 
were seeded in 12-well plates at a density of 5 × 104 cells/well. Equal 
amounts (150 ng) of the different Gata2 reporter constructs ICN1, Master-
mind, dn-Rbpj, shHes1 (MISSION, TRCN0000018989), or irrelevant DNA 
and 150 ng CMV–-Galactosidase plasmids were transfected in triplicate wells. 
Cells were transfected using polyethylenimine (PEI; Polysciences, Inc.). 
(Tomita et al., 1999), although a direct measure of HSC ac-
tivity was not performed. Importantly, here we demonstrate 
that Hes5 (which is functionally equivalent to Hes1) is ex-
pressed de novo in the aorta of Hes1 mutants, which suggests 
the possibility of functional compensation between both pro-
teins. In agreement with this, we found that cumulative de-
letion of Hes1 and Hes5 alleles leads to the generation of 
nonfunctional hematopoietic progenitors in the developing 
AGM and the total absence of HSC activity. In addition, 
we demonstrate that the Gata2 gene is directly activated 
by Notch/RBPJ but repressed by HES-1 specifically in the 
C-Kit+ cell population of the emerging AGM clusters. Thus, 
in Hes-deficient mutants, Gata2 is up-regulated, and the 
number of hematopoietic cluster cells increased, but they 
only contained nonfunctional hematopoietic cells, in agree-
ment with previous work demonstrating that Gata2 levels 
need to be tightly regulated to generate and maintain func-
tional HSCs (Ling et al., 2004; Rodrigues et al., 2005). Our 
experiments show that limiting Notch activity in the absence 
of HES can decrease the levels of Gata2 and partially restore 
the hematopoietic production from AGM cells. Mechanisti-
cally, one possibility is that overexpression of Gata2 in AGM 
cells imposes an impairment to cell cycle entry in the hema-
topoietic progenitor populations, as it was demonstrated in 
the cord blood HSCs (Tipping et al., 2009); however, our 
results indicate that the Hes-deficient endothelium contains 
more proliferative cells, suggesting that AGM subpopulations 
may show specific response to different GATA-2 levels.
Analysis of the Gata2 regulatory regions led to the identi-
fication of two functional DNA-binding sites for Notch/
RBPJ and three for HES, and we demonstrated their rele-
vance in the activation and repression of this gene in the em-
bryonic aorta, the niche of nascent HSCs. As Hes is robustly 
induced by Notch, activation of this pathway in the hemato-
poietic progenitors might induce both positive and negative 
signals in the Gata2 gene, resulting in the so-called type I 
incoherent feed-forward loop (I1-FFL; Mangan and Alon, 
2003), which from our predictions would limit Gata2 activa-
tion in this tissue (Fig. 6 A). These types of circuits have previ-
ously been found to regulate Notch-dependent cell fate 
decisions in Drosophila (Krejcí et al., 2009). Here, we propose 
that after Notch activation, likely through Jagged1, Gata2 and 
Hes genes start to be transcribed until HES protein reaches 
the threshold for repressing the Gata2 promoter. Then Gata2 
transcription decreases, and its mRNA and protein concen-
tration drops, resulting in a pulse-like dynamic that it is re-
quired to achieve limited/transient (producing functional 
progenitors) rather than high/sustained activation (producing 
nonfunctional progenitors; see model in Fig. 6 B). I1-FFLs are 
also known to regulate biphasic responses where the output 
levels (in this case Gata2) depend on the input dose (Notch 
intensity; Kim et al., 2008). By computer modeling, it has been 
demonstrated that I1-FFLs regulate time- or dose-dependent 
biphasic behaviors in a mutually exclusive manner (Kim et al., 
2008), and further work is needed to address whether Gata2 
regulation by Notch and HES follows one of these two models. 
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Ki67 (1:500; Novocastra) were also used. Sections were mounted in Vecta-
shield medium with DAPI.
In situ hybridization. For in situ hybridization, precisely timed embryos 
were fixed overnight at 4°C in 4% paraformaldehyde and embedded in 
OCT (Tissue-Tek). Embryos were sectioned in an RM2135 cryostat (Leica) 
at 16 µm. Digoxigenin-labeled probes were generated from a Bluescript 
plasmid (Agilent Technologies) containing a partial mouse Gata2 cDNA (nt 
170–871) and from plasmid containing Hes1 cDNA and Hes5 cDNA. 
Images were acquired with a BX-60 (Olympus). Representative images were 
edited on Photoshop CS4 software (Adobe).
Transgenic mice: F0 assays. Gata2 promoter inserts from plasmids (p4.0, 
p4.0 muHes, p7.0, and p7.0 muRBP) were purified by NACS PREPAC 
(Gibco), adjusted to 5–10 ng/ml, and injected into mouse oocytes using 
standard strategies. Transgene integration was confirmed by PCR from 
genomic DNA from embryonic tissues. The wild-type constructs p4.0  
(Kobayashi-Osaki et al., 2005) and p7.0 (Minegishi et al., 1999) were previ-
ously described, and point mutations were introduced into these plasmids.
AGM explant culture. The AGM region was dissected and cultured in 
explants for 3 d as previously described (Medvinsky and Dzierzak, 1996). 
In brief, AGMs were deposited on nylon filters (EMD Millipore) placed 
on metallic supports and cultured in myeloid long-term culture medium 
(STEMCELL Technologies) supplemented with 10 µM hydrocortisone 
(Sigma-Aldrich) in an air-liquid interphase. The induction of -actin–CRE-ERT 
transgene was performed by adding 4-OH-tamoxifen (Sigma-Aldrich) every 
36 h to the explant medium at a final concentration of 1 µM.
Hematopoietic colony assay (CFU-C) and CFU-S11 and long-term 
reconstitution assay. The explanted AGMs were digested in 0.12% col-
lagenase (Sigma-Aldrich) in PBS supplemented with 10% FBS for 20 min at 
37°C and used for hematopoietic colony assay (CFU-C), CFU-S11, and 
long-term reconstitution assay experiments. In CFU-C assay, 20,000 cells/
AGM were plated in duplicates in M-3434 semisolid medium (STEMCELL 
Technologies). After 7 d, the presence of hematopoietic colonies was scored 
under the microscope. In CFU-S11 experiments, whole disrupted AGMs 
were injected intravenously in SCID-Beige recipients. SCID-Beige recipi-
ents were previously irradiated at 2.5 Gy. After 11 d, the presence of colonies 
in the spleen was scored under the stereoscope. Some colonies were picked 
and lysed in 0.01 M Tris, pH, 7.4, 0.15 M NaCl, 0.01 M EDTA, and 0.5% 
SDS. From this lysate, Hes1 deletion was detected in both types of colonies, 
CFU-C and CFU-S11, by PCR (primers in Table S4). In long-term recon-
stitution assay experiments, whole disrupted AGMs were injected intrave-
nously in SCID-Beige recipients, with 500,000 white spleen cells from a 
SCID-Beige animal as support cells. SCID-Beige recipients were previously 
irradiated at 2.5 Gy.
Statistics. Statistical analyses were performed using Excel 2011 (Microsoft) 
and SPSS. In Fig. 3 (B–D), Fig. 4 E, and Fig. 5 D, statistical significance was 
assessed using two-tailed Student’s t tests. In Fig. 1 (F and G) and Fig. 2 A, 
statistical significance was assessed using the Spearman test. In Fig. 4 A, sta-
tistical significance was assessed using the Fisher test. In Fig. 5 A, Kruskal–
Wallis and Mann–Whitney U tests were used to assess the significance. In all 
tests, p-values < 0.05 were considered significant. In all experiments: *, P ≤ 
0.05; **, P ≤ 0.01; ***, P ≤ 0.001.
Online supplemental material. Table S1 lists mouse RT-PCR primers. 
Table S2 lists mutagenesis primers. Table S3 lists mouse ChIP primers. Table S4 
lists Hes1 lox-P sites to detect deleted bands. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20120993/DC1.
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(Shimizu and Yamamoto laboratory) for technical assistance. We would like to 
To reduce endogenous ICN1 levels, HEK-293T cells were treated with 
-secretase inhibitor, DAPT (EMD), at 50 µM final concentration for 72 h 
before transfection and during the assay. Luciferase was measured after 48 h 
of transfection according to the manufacturer’s instructions (Luciferase Assay 
System; Promega). Expression levels of transfected proteins were verified by 
Western blot.
ChIP assay. Chromatin was obtained from a pool of 40 dissected AGMs at 
E10.5 or 32D myeloid progenitor cells line. ChIP was performed as previously 
described (Aguilera et al., 2004) with minor modifications. In brief, cross-
linked chromatin from E10.5 dissected AGMs or 32D cell line was sonicated 
for 10 min, medium-power, 0.5-interval, with a Bioruptor (Diagenode) and 
precipitated with anti-RBPJ (Chu and Bresnick, 2004), anti-ICN1 (Abcam), 
and anti-HES1 (H-20 from Santa Cruz Biotechnology, Inc. and N terminus 
from Aviva Systems Biology). After cross-linkage reversal, DNA was used as a 
template for PCR. RT-PCR was performed with SYBR Green I Master 
(Roche) in a LightCycler480 system. Primers used are in Table S3.
Cell culture, viral particle production, and viral infection. 32D cells 
were cultured in Iscove’s and 10% FBS supplemented with 10% WeHi-IL3–
conditioned media. HEK-293T cells were seeded at a density of 5 × 105 
cells/well and transfected with ICN1-IRES-GFP with PEI. Hematopoietic 
cells from disrupted AGMs were incubated in Iscove’s, 10% FBS, 10% IL-3, 
and 10% stem cell factor (SCF)–conditioned medium plus 0.2 µg/ml IL6 and 
0.1 µg/ml Flt3. To assess hematopoietic potential of sorted populations from 
Hes1/Hes5/ mutant mice, 500 CD34+C-Kit+ cells were FACS purified 
and added to confluent cultures of OP9 stromal cells and cultured for up to 
10 d in the presence of 100 ng/ml IL-3, 100 U/ml SCF, 100 ng/ml G-CSF, 
and 200 ng/ml erythropoietin (Epo). Supplemented differentiation medium 
was replaced every 4 d. Cultures were maintained for up to 12 d. Cells were 
harvested by pipetting and examined for hematopoietic development by 
flow cytometry.
Flow cytometry analysis and sorting. The AGM region was dissected 
from E10.5 embryos and dissociated in 0.12% collagenase (Sigma-Aldrich) in 
PBS supplemented with 10% FBS for 30 min at 37°C. The cells were ana-
lyzed by flow cytometry in a FACSCalibur (BD) or FACSAria (BD) and 
FlowJo software (Tree Star). Dead cells were excluded by 7-aminoactino-
mycin-D staining (Molecular Probes) in the FACSCalibur analysis and with 
Hoechst or DAPI in the FACSAria analysis. The YSs and lower trunk re-
gions were harvested from individually dissected embryos washed of mater-
nal blood (Fraser et al., 2002). The anterior regions were used for genotyping 
(Ohtsuka et al., 1999). YSs and lower trunk regions were dissociated with 
0.1% wt/vol collagenase types I and IV (Sigma-Aldrich) for 1 h at 30°C. 
Cells were then blocked with normal mouse serum and incubated with fluor-
escence-conjugated antibodies. For flow cytometric analysis, cells were re-
suspended in Hank’s buffered Saline Solution (Gibco) containing propidium 
iodide (Sigma-Aldrich) for dead cell exclusion. Flow cytometry was per-
formed using a FACSVantage (BD) with CellQuest (BD), and data were 
analyzed using the FlowJo software package. The antibodies CD31-PE, 
Sca1-PE, CD45-FITC, Ter119-PE, CD45-PerCPCy5.5, and CD117-APC 
were purchased from BD and CD41-PeCy7 from eBioscience. VE-cadherin–
APC was generated in-house.
Immunostaining. E10.5 embryos were fixed overnight in 4% paraformal-
dehyde (Sigma-Aldrich) at 4°C and frozen in Tissue-Tek (Sakura). 5-µm 
sections were fixed with 20°C methanol for 15 min and block permeabi-
lized in 10% FBS, 0.3% Surfact-AmpsX100 (Thermo Fisher Scientific), and 
5% nonfat milk in PBS for 90 min at 4°C. Samples were stained with CD31 
(PECAM1 at 1:50; BD) or CD41 (1:50; BD) or C-Kit (CD117 at 1:50; BD) 
in 10% FBS, 5% nonfat milk in PBS overnight, and HRP-conjugated sec-
ondary antibody (Dako) at 1:100 for 90 min and developed with Cy3 or 
coupled tyramide (PerkinElmer). Anti-GFP (MBL) was used at 1:100, and 
Alexa Fluor 488–conjugated donkey anti–rabbit (1:500; Invitrogen) was 
used as a secondary antibody. DeadEnd Fluorimetric System (Promega) and 
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